GJWM
NTLA icon

Gilliland Jeter Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Gilliland Jeter Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-212
Closed -$4.36K – 490
2024
Q3 		$4.36K Hold
212
– – ﹤0.01% 545
2024
Q2 		$4.75K Buy
+212
New +$5.05K ﹤0.01% 523

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gilliland Jeter Wealth Management's NTLA Position: Q4 2024 in Review

Gilliland Jeter Wealth Management sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 212 shares — an estimated $4.36K sold.

Gilliland Jeter Wealth Management first reported a position in NTLA in Q2 2024 and held it in 2 quarters. The position peaked at $4.75K in Q2 2024. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Gilliland Jeter Wealth Management reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Gilliland Jeter Wealth Management sold 212 Intellia Therapeutics shares in Q4 2024, an estimated $4.36K.
  • Gilliland Jeter Wealth Management first reported a position in Intellia Therapeutics in Q2 2024 and held it in 2 quarters.
  • Gilliland Jeter Wealth Management's Intellia Therapeutics position peaked at $4.75K in Q2 2024.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Gilliland Jeter Wealth Management's 13F filing for Q4 2024, filed 28 Jan 2025.